Science AI Journal
Neuroscience · Research topic

Open research questions in Tryptophan and brain disorders

261 unresolved questions extracted from the limitations and future-work sections of 818 Tryptophan and brain disorders papers in our library. Each links back to the study that raised it.

What the literature leaves open

  • Investigate the long-term effects of antipsychotic treatment on inflammatory markers, - Examine the effects of different antipsychotic formulations on the immune system, - Study the relationship between antipsychotic treatment and clinical symptom severity

    Peripheral Inflammatory Profiles in Acute Schizophrenia Relapse: Associations with 6-month Antipsychotic Treatment Coverage · 2026 · DOI

  • The study identifies a gap in understanding the relationship between antipsychotic treatment patterns and peripheral inflammatory markers in acute schizophrenia relapse. There is a need to investigate the potential modulatory effect of antipsychotic treatment on the immune system in schizophrenia. The research aims to address the gap by examining the association between treatment patterns and inflammatory markers.

    Peripheral Inflammatory Profiles in Acute Schizophrenia Relapse: Associations with 6-month Antipsychotic Treatment Coverage · 2026 · DOI

  • The paper identifies a gap in the translation of immune and metabolic concepts into clinical practice in psychiatry. The authors note that while there is a growing understanding of the role of immunity and metabolism in psychiatric disorders, the application of this knowledge in clinical practice remains variable.

    Applying immunity and metabolism to psychiatry: lost, or in translation? · 2026 · DOI

  • The paper identifies the challenge of accelerated aging in individuals with schizophrenia, characterized by an earlier onset of age-related conditions and increased vulnerability to physical and cognitive decline. The study highlights the challenge of social isolation and stigma in shaping health outcomes and quality of life. The paper also notes the challenge of providing effective care strategies for older adults with schizophrenia, given the complexity of their needs and the limited focus on this population in existing research.

    Aging in Schizophrenia: Clinical, Biological, and Psychosocial Perspectives · 2026 · DOI

  • Limited focus on older populations - Significant gaps in longitudinal research - The term 'neuroinflammation' is frequently used in the context of schizophrenia, but its application remains controversial

    Aging in Schizophrenia: Clinical, Biological, and Psychosocial Perspectives · 2026 · DOI

  • The lack of prospective registration, independent screening and extraction, and validated risk-of-bias assessment. The absence of a reproducible chain linking authenticated and chemically defined materials to dose, exposure, pharmacological endpoint, and clinical outcome. The heterogeneity of study designs, outcomes, and incomplete numerical reporting, which precluded quantitative pooling and meta-analysis.

    Review Areca Thirteen Pill (GY-13) for depression: a ConPhyMP-Informed critical review of material definition, pharmacological evidence, and translational Heyi-neuroplasticity-stress hypotheses · 2026 · DOI

  • Further investigation of GY-13 is justified, - Validation studies for the HNS framework are proposed, - Research on the reproducible chain linking authenticated and chemically defined materials to dose, exposure, pharmacological endpoint, and clinical outcome is needed

    Review Areca Thirteen Pill (GY-13) for depression: a ConPhyMP-Informed critical review of material definition, pharmacological evidence, and translational Heyi-neuroplasticity-stress hypotheses · 2026 · DOI

  • further study of the mechanisms of depression, - exploration of the biological pathways associated with NeuroPro-Dep

    Multimodal fusion of brain imaging and proteomics reveals a brain–body pathway linking depression and metabolic dysfunction · 2026 · DOI

  • A lack of holistic examination of interactions between plasma proteins and brain features in depression. Limited understanding of the brain-body interactions in the etiopathology of psychiatric disorders. A need for a better in-depth understanding of the pathological pathways underlying depression.

    Multimodal fusion of brain imaging and proteomics reveals a brain–body pathway linking depression and metabolic dysfunction · 2026 · DOI

  • There is a gap in understanding the relationship between antipsychotic drug dose and cognitive deficits in schizophrenia patients. The study aims to investigate this relationship using a cross-sectional and observational study design.

    Investigating the relationship between Toll-like receptor activity, low-grade inflammation, cognitive deficits, and antipsychotic drug dose in schizophrenia patients: a moderation analysis · 2026 · DOI

  • potential influence of age-related vascular lesions and late life multimorbidity, - limited to unmedicated BDII-D individuals, - small sample size for some analyses

    Disrupted brain functional network topology is associated with peripheral inflammation in unmedicated bipolar II depression · 2026 · DOI

  • further exploration of the role of inflammation in BDII, - investigation of the relationship between functional network topology and inflammation markers in medicated BDII-D

    Disrupted brain functional network topology is associated with peripheral inflammation in unmedicated bipolar II depression · 2026 · DOI

  • The study used a person-centered analytic approach, which may not capture the full range of individual differences. The sample was limited to UK Biobank participants, which may not be representative of other populations. The study relied on self-reported data, which may be subject to biases and errors. The analysis was restricted to two donors for the imaging-transcriptomic analyses, which may limit the generalizability of the findings. The study did not control for all potential confounding variables.

    Adversity as the key feature: neuroimaging profiles of subtypes from multiple depression risk factors · 2026 · DOI

  • Future studies should investigate the longitudinal relationships between adversity profiles and depression outcomes. Research should examine the neural mechanisms underlying the associations between adversity profiles and depression risk. Studies should explore the potential applications of latent class analysis in identifying distinct profiles of risk factors for other mental health conditions. Future research should investigate the effectiveness of targeted interventions for individuals with different adversity profiles.

    Adversity as the key feature: neuroimaging profiles of subtypes from multiple depression risk factors · 2026 · DOI

  • The study did not construct a generalized model. Transcriptomic data exhibit substantial temporal and spatial variability. The sample size was limited to 141 individuals with MDD and 134 healthy controls

    Peripheral transcriptomic aging acceleration in major depressive disorder: the mediating role of insular cortex alterations · 2026 · DOI

  • Further studies are needed to develop a universally applicable transcriptomic aging clock. Research should investigate the relationship between transcriptomic aging and other biological aging clocks. Studies should examine the impact of transcriptomic aging on MDD risk in larger and more diverse populations

    Peripheral transcriptomic aging acceleration in major depressive disorder: the mediating role of insular cortex alterations · 2026 · DOI

  • Temporal and causal inference are limited by the use of retrospective or case-control designs in prior studies. The underlying immunometabolic mechanisms by which recent stressful life events contribute to schizophrenia risk are complex and not well understood. Identifying specific biomarkers that mediate the association between recent stressful life events and subsequent schizophrenia risk is a challenge.

    Recent stressful life events, immunometabolic markers, and risk of schizophrenia: A prospective cohort study · 2026 · DOI

  • Investigation of stress-related pathways to psychosis, - Research on the mechanisms by which recent SLEs contribute to schizophrenia risk, - Study of the role of immunometabolic markers in schizophrenia

    Recent stressful life events, immunometabolic markers, and risk of schizophrenia: A prospective cohort study · 2026 · DOI

  • many studies have important limitations - comparison group consisting of people who would be never eligible for the target immunomodulatory treatment in clinical practice - most lack overt neurological signs

    Immune dysregulation in depression and psychosis: summary of current evidence and future perspectives · 2026 · DOI

  • applying target trial emulation to data from large-scale administrative registers - linkages of administrative registers with biomarker data - RCTs of immunotherapy in psychosis

    Immune dysregulation in depression and psychosis: summary of current evidence and future perspectives · 2026 · DOI

  • The complex and incompletely understood pathophysiology of depression poses a challenge. The heterogeneous nature of depression makes it difficult to develop effective therapeutic strategies. The need to integrate recent advances in molecular neuroscience and psychiatric research is a challenge.

    Cell death pathways in the pathogenesis of depression: mechanisms and therapeutic implications · 2026 · DOI

  • The current understanding of cell death pathways in depression is incomplete. The interactions between cell death pathways and key pathological processes implicated in depression are not fully understood. There is a need for novel therapeutic strategies targeting cell death-associated signaling pathways.

    Cell death pathways in the pathogenesis of depression: mechanisms and therapeutic implications · 2026 · DOI

  • The complex interplay between metabolic biomarkers, brain metrics, and PCOS status. The need to account for non-linearity and threshold effects in the associations between metabolic biomarkers and depression. The challenge of identifying the underlying mechanism linking PCOS to depression.

    From metabolic network to brain loop: unraveling the neuro-metabolic correlates in PCOS-related depression · 2026 · DOI

  • Further research is needed to fully elucidate the underlying mechanism linking PCOS to depression, - Investigating other potential factors contributing to PCOS-related depression, - Examining the effects of interventions targeting the metabolic and brain structural pathways on PCOS-related depression

    From metabolic network to brain loop: unraveling the neuro-metabolic correlates in PCOS-related depression · 2026 · DOI

  • integrating validated proteomic panels with genetic data to enable personalized therapeutic strategies, - large-scale validation that provides essential insights into generalizability and true effect sizes, - rigorous, large-scale validation of proteomic findings

    Blood-based proteomics for schizophrenia: candidate biomarkers for risk assessment and precision psychiatry · 2026 · DOI

Most-cited papers in Tryptophan and brain disorders

Most recent work

Find a gap in your own Tryptophan and brain disorders sub-topic

This page shows what the Tryptophan and brain disorders literature already flags as unresolved. To narrow it to your specific question, run the guided finder — it searches the gap library on demand and checks candidates against 250M+ OpenAlex works.

Open the Research Gap Finder →

Related topics in Neuroscience

Autism Spectrum Disorder Research
1,667 open questions
Memory Processes and Influences
744 open questions
Neural and Behavioral Psychology Studies
697 open questions
Psychology of Moral and Emotional Judgment
544 open questions
Neurobiology of Language and Bilingualism
491 open questions
Hearing Loss and Rehabilitation
465 open questions
Functional Brain Connectivity Studies
439 open questions
Visual perception and processing mechanisms
367 open questions
261 open questions have been extracted from the limitations and future-work passages of 818 Tryptophan and brain disorders papers in our library. Each one below links back to the study that raised it, so you can read the original claim in context.

Tools for your next paper

Gaps & Literature SearchFind open questions in any field — 120,000+ open gaps mined from our own library.Pre-CheckIs your paper ready? A Tier 1–5 acceptance probability in seconds.Journal FinderA ranked shortlist of target journals from a 17,500-venue index.Duplicate Publication CheckerCheck prior-publication & salami-slicing risk across 8 sources.Citation GeneratorFreeA DOI or title → APA, MLA, Vancouver, Chicago, BibTeX, RIS. No signup.Graphical Abstract MakerFreeTurn your findings into a colorblind-safe graphical abstract.

Compare the category — Honest roundups of the AI research tools, ours listed alongside the alternatives.

Command palette

Jump anywhere, run any action.